Pathology and diagnostic pitfalls of cholangiocarcinoma: Rising incidence of an old cancer

Pathology Case Reviews

Volumn 14, Issue 1, 2009, Pages 28-33

  Pritchard, Colin C ^a,b   Yeh, Matthew M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Bile duct; Cholangiocarcinoma; ICC; Immunohistochemistry; Intrahepatic

Indexed keywords

ALPHA FETOPROTEIN; NERVE CELL ADHESION MOLECULE;

ADENOCARCINOMA; ADULT; BILE DUCT CARCINOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DYSPLASIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METASTASIS; PARTIAL HEPATECTOMY; PATHOLOGY; PHENOTYPE; PHYSICAL EXAMINATION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; TREMATODIASIS;

EID: 68549115569     PISSN: 10829784     EISSN: 15334015     Source Type: Journal    
DOI: 10.1097/PCR.0b013e31819c4b66     Document Type: Review

References (37)

1. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115-125.
2. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005;128:620-626.
3. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004; 40:472-477.
4. Khan SA, Taylor-Robinson SD, Toledano MB, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806-813.
5. Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholan-giocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004; 99:523-526.
6. Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg. 2002;89:962-970.
7. Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer. 2000;88:2471-2477.
8. Torbenson M, Yeh MM, Abraham SC. Bile duct dysplasia in the setting of chronic hepatitis C and alcohol cirrhosis. Am J Surg Pathol. 2007;31:1410 -1413.
9. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999;10(suppl 4):308-311.
10. Rullier A, Le Bail B, Fawaz R, et al. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol. 2000;24:870-876.
11. Aishima S, Kuroda Y, Nishihara Y, et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am J Surg Pathol. 2007;31:1059-1067.
12. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med. 1965;38:241-256.
13. Suzuki M, Takahashi T, Ouchi K, et al. The development and extension of hepatohilar bile duct carcinoma. A three-dimensional tumor mapping in the intrahepatic biliary tree visualized with the aid of a graphics computer system. Cancer. 1989;64:658-666.
14. Weinbren K, Mutum SS. Pathological aspects of cholangiocarcinoma. J Pathol. 1983;139:217-238.
15. Nakajima T, Kondo Y. Well-differentiated cholangiocarcinoma: diagnostic significance of morphologic and immunohistochemical parameters. Am J Surg Pathol. 1989;13:569-573.
16. Kajiyama K, Maeda T, Takenaka K, et al. The significance of stromal desmo-plasia in intrahepatic cholangiocarcinoma: a special reference of "scirrhous-type" and "nonscirrhous-type" growth. Am J Surg Pathol. 1999;23:892-902.
17. Hurlimann J, Gardiol D. Immunohistochemistry in the differential diagnosis of liver carcinomas. Am J Surg Pathol. 1991;15:280-288.
18. Stroescu C, Herlea V, Dragnea A, et al. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocel-lular carcinomas from intrahepatic cholangiocarcinomas. J Gastrointestin Liver Dis. 2006;15: 9-14.
19. Chu PG, Schwarz RE, Lau SK, et al. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol. 2005;29: 359-367.
20. Mosnier JF, Kandel C, Cazals-Hatem D, et al. N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod Pathol. In press.
21. Lau SK, Prakash S, Geller SA, et al. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic ad-enocarcinoma. Hum Pathol. 2002;33:1175-1181.
22. Geramizadeh B, Boub R, Rahsaz M. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls. Indian J Pathol Microbiol. 2007;50:507-510.
23. Shiran MS, Isa MR, Sherina MS, et al. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma. Malays J Pathol. 2006; 28:87-92.
24. Morrison C, Marsh W Jr, Frankel WL. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol. 2002;15:1279-1287.
25. Maeda T, Adachi E, Kajiyama K, et al. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol. 1995;26:956-964.
26. Tickoo SK, Zee SY, Obiekwe S, et al. Combined hepatocellular-cholangio- carcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol. 2002;26:989-997.
27. Lee WS, Lee KW, Heo JS, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholan-giocarcinoma. Surg Today. 2006;36:892-897.
28. Wu PC, Fang JW, Lau VK, et al. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol. 1996;149:1167-1175.
29. Klein WM, Molmenti EP, Colombani PM, et al. Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol. 2005;124:512- 518.
30. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006;49:138-151.
31. Fischer HP, Altmannsberger M, Weber K, et al. Keratin polypeptides in malignant epithelial liver tumors. Differential diagnostic and histogenetic aspects. Am J Pathol. 1987;127:530-537.
32. Goldstein NS, Bassi D. Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol. 2001;115:695-702.
33. Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol. 2005;29:381-389.
34. Zen Y, Adsay NV, Bardadin K, et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol. 2007;20:701-709.
35. Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol. 2004;99:1675-1681.
36. DeHaan RD, Kipp BR, Smyrk TC, et al. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcino-mas. Hum Pathol. 2007;38:491-499.
37. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology. 2006;131:1064-1072.